Scaled Average Bioequivalence [Regulatives / Guidelines]

posted by graveendranath – 2010-01-06 08:36 (6005 d 06:14 ago) – Posting: # 4563
Views: 7,580

Dear Helmut,

We want to conduct a study with partial replicated design (Reference twice) for Europe regulatory. My doubt is

1. Does the Europe Regulatory accepts the Scaled Average Bioequivalence method for highly variable drugs?
2. If we can show that the Intra cv for reference product is > 30% then can we use wider limits (75-133)?

Thank You

Rgds
Raveendranath

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
182 visitors (0 registered, 182 guests [including 86 identified bots]).
Forum time: 15:50 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5